vs
安捷伦科技（A）与TENET HEALTHCARE CORP（THC）财务数据对比。点击上方公司名可切换其他公司
TENET HEALTHCARE CORP的季度营收约是安捷伦科技的3.1倍（$5.5B vs $1.8B）。安捷伦科技净利率更高（17.0% vs 11.7%，领先5.3%）。TENET HEALTHCARE CORP同比增速更快（9.0% vs 7.0%）。TENET HEALTHCARE CORP自由现金流更多（$367.0M vs $175.0M）。过去两年安捷伦科技的营收复合增速更高（6.9% vs 1.5%）
安捷伦科技是全球知名的生命科学、诊断与应用化学领域解决方案提供商，旗下生命科学与应用市场业务板块提供液相色谱系统及组件、液相色谱质谱联用系统、气相色谱设备、电感耦合等离子体质谱仪、原子吸收仪等多种分析检测仪器，服务全球各领域客户。
Tenet Healthcare Corporation是总部位于美国达拉斯的营利性跨国医疗服务企业，旗下拥有USPI等多个品牌、子公司、合资企业及合作主体，运营65家医院及超过450个医疗设施，还通过旗下Conifer Health Solutions为各类医疗系统及其他客户提供专业医疗支持服务
A vs THC — 直观对比
营收规模更大
THC
是对方的3.1倍
$1.8B
营收增速更快
THC
高出2.0%
7.0%
净利率更高
A
高出5.3%
11.7%
自由现金流更多
THC
多$192.0M
$175.0M
两年增速更快
A
近两年复合增速
1.5%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.8B | $5.5B |
| 净利润 | $305.0M | $644.0M |
| 毛利率 | 52.6% | — |
| 营业利润率 | 19.6% | 15.4% |
| 净利率 | 17.0% | 11.7% |
| 营收同比 | 7.0% | 9.0% |
| 净利润同比 | -4.1% | 12.6% |
| 每股收益（稀释后） | $1.07 | $4.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATHC
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $5.5B | ||
| Q3 25 | $1.7B | $5.3B | ||
| Q2 25 | $1.7B | $5.3B | ||
| Q1 25 | $1.7B | $5.2B | ||
| Q4 24 | $1.7B | $5.1B | ||
| Q3 24 | $1.6B | $5.1B | ||
| Q2 24 | $1.6B | $5.1B |
净利润ATHC
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $644.0M | ||
| Q3 25 | $336.0M | $579.0M | ||
| Q2 25 | $215.0M | $522.0M | ||
| Q1 25 | $318.0M | $622.0M | ||
| Q4 24 | $351.0M | $572.0M | ||
| Q3 24 | $282.0M | $681.0M | ||
| Q2 24 | $308.0M | $477.0M |
毛利率ATHC
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | — | ||
| Q3 25 | 51.1% | — | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 53.5% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 54.4% | — |
营业利润率ATHC
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | 15.4% | ||
| Q3 25 | 20.7% | 16.8% | ||
| Q2 25 | 18.0% | 15.6% | ||
| Q1 25 | 22.4% | 18.1% | ||
| Q4 24 | 24.0% | 16.2% | ||
| Q3 24 | 21.1% | 21.3% | ||
| Q2 24 | 23.1% | 14.9% |
净利率ATHC
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | 11.7% | ||
| Q3 25 | 19.3% | 10.9% | ||
| Q2 25 | 12.9% | 9.9% | ||
| Q1 25 | 18.9% | 11.9% | ||
| Q4 24 | 20.6% | 11.3% | ||
| Q3 24 | 17.9% | 13.3% | ||
| Q2 24 | 19.6% | 9.3% |
每股收益（稀释后）ATHC
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $4.22 | ||
| Q3 25 | $1.18 | $3.86 | ||
| Q2 25 | $0.75 | $3.14 | ||
| Q1 25 | $1.11 | $4.27 | ||
| Q4 24 | $1.23 | $3.79 | ||
| Q3 24 | $0.97 | $4.89 | ||
| Q2 24 | $1.05 | $2.64 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.8B | $2.9B |
| 总债务越低越好 | $3.0B | $13.1B |
| 股东权益账面价值 | $6.9B | $4.2B |
| 总资产 | $12.8B | $29.7B |
| 负债/权益比越低杠杆越低 | 0.44× | 3.10× |
8季度趋势，按日历期对齐
现金及短期投资ATHC
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $2.9B | ||
| Q3 25 | $1.5B | $3.0B | ||
| Q2 25 | $1.5B | $2.6B | ||
| Q1 25 | $1.5B | $3.0B | ||
| Q4 24 | $1.3B | $3.0B | ||
| Q3 24 | $1.8B | $4.1B | ||
| Q2 24 | $1.7B | $2.9B |
总债务ATHC
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | $13.1B | ||
| Q3 25 | $3.4B | $13.1B | ||
| Q2 25 | $3.3B | $13.1B | ||
| Q1 25 | $3.3B | $13.1B | ||
| Q4 24 | $3.3B | $13.1B | ||
| Q3 24 | $2.1B | $12.8B | ||
| Q2 24 | $2.1B | $12.8B |
股东权益ATHC
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $4.2B | ||
| Q3 25 | $6.4B | $4.0B | ||
| Q2 25 | $6.1B | $3.7B | ||
| Q1 25 | $6.0B | $4.2B | ||
| Q4 24 | $5.9B | $4.2B | ||
| Q3 24 | $5.9B | $3.8B | ||
| Q2 24 | $6.2B | $3.5B |
总资产ATHC
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $29.7B | ||
| Q3 25 | $12.2B | $29.4B | ||
| Q2 25 | $12.2B | $28.7B | ||
| Q1 25 | $11.9B | $29.2B | ||
| Q4 24 | $11.8B | $28.9B | ||
| Q3 24 | $11.0B | $29.4B | ||
| Q2 24 | $10.9B | $29.3B |
负债/权益比ATHC
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | 3.10× | ||
| Q3 25 | 0.53× | 3.26× | ||
| Q2 25 | 0.55× | 3.49× | ||
| Q1 25 | 0.56× | 3.13× | ||
| Q4 24 | 0.57× | 3.14× | ||
| Q3 24 | 0.36× | 3.33× | ||
| Q2 24 | 0.34× | 3.67× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $268.0M | $731.0M |
| 自由现金流经营现金流 - 资本支出 | $175.0M | $367.0M |
| 自由现金流率自由现金流/营收 | 9.7% | 6.6% |
| 资本支出强度资本支出/营收 | 5.2% | 6.6% |
| 现金转化率经营现金流/净利润 | 0.88× | 1.14× |
| 过去12个月自由现金流最近4个季度 | $993.0M | $2.5B |
8季度趋势，按日历期对齐
经营现金流ATHC
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $731.0M | ||
| Q3 25 | $362.0M | $1.1B | ||
| Q2 25 | $221.0M | $936.0M | ||
| Q1 25 | $431.0M | $815.0M | ||
| Q4 24 | $481.0M | $-331.0M | ||
| Q3 24 | $452.0M | $1.0B | ||
| Q2 24 | $333.0M | $747.0M |
自由现金流ATHC
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $367.0M | ||
| Q3 25 | $259.0M | $778.0M | ||
| Q2 25 | $107.0M | $743.0M | ||
| Q1 25 | $334.0M | $642.0M | ||
| Q4 24 | $388.0M | $-661.0M | ||
| Q3 24 | $360.0M | $829.0M | ||
| Q2 24 | $230.0M | $602.0M |
自由现金流率ATHC
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | 6.6% | ||
| Q3 25 | 14.9% | 14.7% | ||
| Q2 25 | 6.4% | 14.1% | ||
| Q1 25 | 19.9% | 12.3% | ||
| Q4 24 | 22.8% | -13.0% | ||
| Q3 24 | 22.8% | 16.2% | ||
| Q2 24 | 14.6% | 11.8% |
资本支出强度ATHC
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 6.6% | ||
| Q3 25 | 5.9% | 5.3% | ||
| Q2 25 | 6.8% | 3.7% | ||
| Q1 25 | 5.8% | 3.3% | ||
| Q4 24 | 5.5% | 6.5% | ||
| Q3 24 | 5.8% | 4.2% | ||
| Q2 24 | 6.5% | 2.8% |
现金转化率ATHC
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | 1.14× | ||
| Q3 25 | 1.08× | 1.83× | ||
| Q2 25 | 1.03× | 1.79× | ||
| Q1 25 | 1.36× | 1.31× | ||
| Q4 24 | 1.37× | -0.58× | ||
| Q3 24 | 1.60× | 1.53× | ||
| Q2 24 | 1.08× | 1.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
THC
| Other | $2.9B | 52% |
| Health Care Patient Service | $1.4B | 25% |
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $1.2B | 22% |
| Health Care Other Sources | $56.0M | 1% |
